Form 4 for CCCC C4 Therapeutics, Inc.
Accepted 2026-01-05 00:00:00 ET · period of report 2026-01-02 · accession 0001470831-26-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-05 | 2026-01-02 | CCCC | GROGAN DONNA ROY | Dir | A - Grant | $1.93 | +7,513 | 66.1K | +13% | +$14.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-02 | A | A | 7,513 | $1.93 | 66,142 | D | — | — | (F2) The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 2, 2026. |